The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The VITA-FAST tokens have been met with overwhelming interest
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Subscribe To Our Newsletter & Stay Updated
